Brief: Equillium Announces Update To EQUALISE Study Of Itolizumab In Patients With Systemic Lupus Erythematosus And Lupus Nephritis
11/08/2021 21:48
Aug 11 (Reuters) - Equillium Inc EQ.O :
* EQUILLIUM ANNOUNCES UPDATE TO EQUALISE STUDY OF ITOLIZUMAB
IN
PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND LUPUS NEPHRITIS
* EQUILLIUM INC - EQUILLIUM EXPECTS TO ANNOUNCE INTERIM DATA
FROM
TYPE B PORTION OF STUDY BY END OF YEAR
* EQUILLIUM INC - HAS RECEIVED FAST TRACK DESIGNATION FROM
FDA FOR
ITOLIZUMAB FOR TREATMENT OF PATIENTS WITH LUPUS NEPHRITIS
Source text for Eikon: ID:nBw2BF0nQa
Further company coverage: EQ.O
Recent news on Equillium
See all newsBrief: Equillium Receives Australian Regulatory Clearance To Initiate First-In-Human Clinical Trial Of Eq504
Equillium Inc reports results for the quarter ended June 30 - Earnings Summary
Equillium Q2 post narrower net loss than expected; starts R&D initiatives
Equillium Inc expected to post a loss of 5 cents a share - Earnings Preview
Equillium Q1 net loss, profit miss analyst expectations